Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Our Products
MouseAtlas
iPSC Cell Lines
Knockout Cell Lines
Tumor Cell Lines
Adeno-associated Virus (AAV) Standard Capsid
Featured Catalog
Humanized Mouse Models
HUGO-Ab™
Target-Humanized Mouse Models (HUGO-GT™)
Target-Humanized Mouse Models (CDS)
Humanized Immune System Mouse Models
Tool Mice
Cre Mouse Lines
Disease Models
Autoimmune Disease Models
Ophthalmic Disease Models
Immunodeficient Mouse Models
Metabolic Disease Models
Neurological Disease Models
Oncology & Immuno-oncology Models
Custom Model Services
Model Generation Techniques
Turboknockoutᵀᴹ Gene Targeting
Cre-ESCs Gene Editing
Targeted Gene Editing
Genetically Engineered Animals
Knockin Mice
Knockin Rats
Knockout Mice
Knockout Rats
Transgenic Mice
Transgenic Rats
Transgenic Model Generation
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Adenovirus Packaging
Lentivirus Packaging
Custom Cell Line Services
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Overexpression Cell Lines
Point Mutation Cell Lines
Breeding & Supporting Services
BAC Modification
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
Preclinical Solutions
Antibody Discovery Platform
HUGO-Mab™
HUGO-Light™
HUGO-Nano™
HUGO-Ab-eKO™
Therapeutic Area
Neurology
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
Huntington's Disease (HD)
Blood Brain Barrier (BBB)
Neuropathic Pain
Metabolic
Obesity
MASH & MASLD
Cardiovascular
Ophthalmology
Glaucoma
Age-Related Macular Degeneration (AMD)
Retinal-related diseases
Oncology
PBMC Humanized Mouse Model
Human Immune System (HIS) Mouse Model
Immunology & Inflammation
Asthma
Drug Classification
Therapeutic Antibody Drugs
Monoclonal Antibodies (mAb)
Bispecific Antibodies (BsAb)
ADC/AOC
AI-Powered AAV Discovery
Cell Immunotherapy
Gene Therapy
Oligonucleotide Therapy
Fully Human Antibody Library
Neurology Antibodies
Metabolic & Cardiovascular Antibodies
Ophthalmology Antibodies
Oncology Antibodies
Immunology & Inflammation Antibodies
Resources
News
Blogs & Insight
Promotion
Events & Webinars
Databases
AbSeek
Rare Disease Data Center
Cell iGeneEditor™ System
iCyagen
Citations
Resource Vault
OriCell
About Us
Animal Health & Welfare
Company Overview
Facility Overview
Our Team
Our Partners
Careers
Health Reports
Contact Us
Login
HomeBlogs & InsightsBALB/c vs C57BL/6 Mice: Key Differences and How to Choose
Animal Science and Quality

BALB/c vs C57BL/6 Mice: Key Differences and How to Choose

Cyagen Technical Content Team | June 10, 2025
Find the Models with BALB/c or C57BL/6 Strains You Need
Explore Cyagen mouse model library with 20,000+ pre-validated strains available for immediate selection.
Find the Models with BALB/c or C57BL/6 Strains You Need
Contents
01. BALB/c vs C57BL/6 Mice: Key Differences and How to Choose 02. Difference Between BALB/c and C57BL/6 Mice 03. C57BL/6: The Default Background for Genetic Engineering 04. BALB/c: The Workhorse for Antibodies, Allergy and Tumor Immunology 05. Immunological Differences Between C57BL/6 and BALB/c 06. Choosing a Genetic Modification Approach 07. References

Updated on 2026/10/26

C57BL/6 and BALB/c are two of the most widely used inbred mouse strains in biomedical research. They differ in immune polarization, MHC haplotype, disease susceptibility, metabolism and behavior, so the right choice depends on your research question, the phenotype you need to measure, and the background of any models you plan to cross with.

Unlike outbred stocks, which retain genetic diversity, inbred strains are produced by at least 20 consecutive generations of brother–sister mating, leaving animals nearly genetically identical and homozygous at almost all loci. This reduces genetic variability and supports reproducibility, although experimental conditions still influence results.

Genetic background is not neutral: the same mutation can differ in phenotype, penetrance or expressivity across strains. Choosing a background before you design or order a model avoids costly backcrossing and misinterpreted results.

This article covers:

  1. Key characteristics of C57BL/6 and BALB/c mice
  2. Immunological differences of C57BL/6 and BALB/c mice
  3. How to choose a strain and a genetic modification approach for your model

Quick answer: Choose C57BL/6 for most genetically engineered models, metabolic and cardiovascular studies, Th1-type cell-mediated immunity, and B16, MC38 or LLC tumor models. Choose BALB/c for hybridoma-based antibody production, Th2-type allergy and asthma models, Leishmania major susceptibility studies, and 4T1 or CT26 tumor models. Whichever strain you use, keep the substrain (e.g., C57BL/6J vs C57BL/6N) consistent across experimental and control groups.

Difference Between BALB/c and C57BL/6 Mice

When comparing BALB/c vs C57BL/6 mice, key differences include coat color, MHC haplotype, immune tendencies, substrain-specific variants, and research applications. The table below summarizes the difference between BALB/c and C57BL/6 mice across these features to help researchers select a strain suited to their experimental model and study objectives.

Feature C57BL/6 BALB/c
Coat color Black (a/a) Albino (Tyrc)
MHC haplotype H2b H2d
T helper bias Often Th1-leaning Often Th2-leaning
Macrophage bias May exhibit stronger NO-associated macrophage responses under certain stimulation conditions May exhibit higher arginase-associated macrophage responses under certain stimulation conditions
Common substrains C57BL/6J, C57BL/6N BALB/cJ, BALB/cByJ, BALB/cAnN
Notable variants Nnt deletion (6J); Crb1rd8 (many 6N substrains); Cdh23ahl Cdh23ahl in BALB/c substrains
Typical uses Genetic engineering, metabolism and DIO, atherosclerosis (Apoe/Ldlr KO), syngeneic tumors (B16, MC38) Hybridoma-based monoclonal antibodies, allergy and asthma (OVA), syngeneic tumors (4T1, CT26), vaccine studies
Behavior High alcohol preference; anxiety varies by assay Often higher anxiety-like behavior in some assays

Immune tendencies depend on the model, stimulus and experimental conditions.

C57BL/6: The Default Background for Genetic Engineering

C57BL/6 is the most widely used inbred mouse strain, and C57BL/6J is the basis of the mouse reference genome, first published as a draft in 2002 [1]. The International Mouse Phenotyping Consortium (IMPC) uses C57BL/6N, providing extensive phenotyping data for interpreting models on the same background.

Figure 1. C57BL/6 mice.
Figure 1. C57BL/6 mice.

C57BL/6 mice key characteristics:

  • Genetic engineering: Established ES cell lines, a well-annotated reference genome and extensive genetic resources make C57BL/6 the default background for knockout, knock-in and conditional models.
  • Metabolism: Widely used for diet-induced obesity (DIO), insulin resistance and glucose intolerance studies; responses vary with substrain, sex, diet and feeding duration.
  • Cardiovascular: The standard background for Apoe and Ldlr knockout atherosclerosis models.
  • Tumors: Low spontaneous mammary tumor incidence. Hosts widely used syngeneic lines such as B16 melanoma, MC38 colon carcinoma and Lewis lung carcinoma (LLC).
  • Behavior: Higher voluntary alcohol consumption than most inbred strains; widely used in addiction research [2].
  • Infection: Relatively resistant to Mycobacterium tuberculosis compared with susceptible strains such as C3H and DBA/2 [3], and resistant in classical Leishmania major and ectromelia (mousepox) models.
  • Hearing: C57BL/6J carries the Cdh23 age-related hearing loss allele (ahl), which contributes to progressive hearing loss [4]; consider age and auditory function when interpreting behavioral tests.

Substrains matter: C57BL/6J vs C57BL/6N

The J (The Jackson Laboratory) and N (NIH) substrains separated in the 1950s and now differ at known loci [5]:

  • C57BL/6J carries an in-frame deletion in Nnt (nicotinamide nucleotide transhydrogenase), which can contribute to impaired insulin secretion and glucose intolerance [6].
  • Many C57BL/6N-derived substrains carry Crb1rd8, which can cause retinal lesions and confound eye phenotyping [7]; confirm the genotype of the colony used.

Do not use J and N animals interchangeably as controls, and confirm the substrain of every model you cross. Substrain-specific variants can introduce unintended phenotypes or confound the interpretation of genetically engineered mouse studies, particularly when experimental animals and controls come from different substrain backgrounds.

BALB/c: The Workhorse for Antibodies, Allergy and Tumor Immunology

BALB/c is an albino inbred strain widely used in immunology, oncology, infectious disease and antibody production. Its Th2 tendency in many settings and established hybridoma workflows make it a common choice for antibody and allergy work.

Figure 2. BALB/c mice.
Figure 2. BALB/c mice.

BALB/c mice key characteristics:

  • Antibody production: BALB/c immunization and BALB/c-derived myeloma lines underpin hybridoma-based monoclonal antibody production [8]; the strain is also susceptible to mineral oil-induced plasmacytomas.
  • Allergy and asthma: Develops IgE responses and airway hyperresponsiveness under established sensitization and challenge protocols, making it a common strain for ovalbumin (OVA) asthma models.
  • Tumors: Low spontaneous mammary tumor incidence in colonies free of exogenous mouse mammary tumor virus (MMTV). Hosts syngeneic lines such as 4T1 breast carcinoma and CT26 colon carcinoma. Lung and renal tumors occur in some aging colonies, varying by substrain.
  • Infection: Susceptible in classical Leishmania major models, developing progressive lesions associated with a Th2 response [9], and relatively susceptible in common Listeria monocytogenes and ectromelia models [10,13].
  • Behavior: Often shows more anxiety-like behavior than C57BL/6, though the direction of the difference depends on the test and conditions [14].
  • Hearing: BALB/cByJ is susceptible to age-related hearing loss associated with the ahl locus [15]; check the auditory phenotype of the substrain and age group used.

Like C57BL/6, BALB/c has distinct substrains (BALB/cJ, BALB/cByJ, BALB/cAnN); record the substrain and keep it consistent across experimental and control groups.

Immunological Differences Between C57BL/6 and BALB/c

Immune phenotype is often the deciding factor. The two strains differ in both adaptive and innate immunity [11].

Th1 vs Th2 polarization. C57BL/6 mice often show Th1-leaning responses with more IFN-γ, whereas BALB/c mice are more readily driven toward Th2 responses with more IL-4. In classical Leishmania major models, C57BL/6 mice control infection through a Th1 response, while BALB/c mice develop progressive, Th2-associated disease [9]. These tendencies do not predict responses to every antigen or pathogen.

Innate immunity. Under some stimulation conditions, C57BL/6 macrophages produce more nitric oxide and BALB/c macrophages show greater arginase activity, historically described as M1- versus M2-leaning activation [12]; these responses depend on stimulus and tissue. Strain differences in early dendritic cell IL-12 and IL-15 production have also been linked to responses to Listeria monocytogenes [13].

MHC haplotype. The mouse MHC (H2 complex) contains both class I and class II genes. C57BL/6 carries the H2b haplotype and BALB/c carries H2d, which determines the peptides presented to T cells. MHC-restricted reagents such as tetramers, TCR-transgenic lines and defined epitopes must therefore match the strain, and some anti-MHC antibodies are haplotype-specific, so confirm compatibility before staining.

Practical implications

  • Consider C57BL/6 for cell-mediated immunity and Th1/Th17-associated autoimmunity models.
  • Consider BALB/c for hybridoma-based antibody production, allergy and asthma, and infection models in which its susceptibility is established.
  • For syngeneic transplantation, match donor and recipient genetic backgrounds; MHC matching alone does not exclude rejection due to minor histocompatibility differences.

Choosing a Genetic Modification Approach

Two widely used approaches for generating custom genetically engineered mouse models are direct embryo editing and ES cell-based gene targeting. The choice depends on the intended modification, genetic background, and validation requirements.

Feature Targeted Gene Editing-Pro ES cell-based targeting (TurboKnockout™)
Common uses Knockouts, point mutations and many knock-ins Large knock-ins, humanized and complex conditional alleles
Timeline Founders in a few months; breeding and validation add time As few as 6–8 months for selected projects; scope-dependent
Strain flexibility Multiple strains and species with suitable embryo-editing workflows Requires suitable germline-competent ES cells
Validation Intended allele, relevant off-target risks and unintended target-site changes Targeted allele, vector integration and chromosome integrity
Founder considerations F0 mosaicism may occur; verify transmitted alleles in offspring Typically produces chimeras; verify germline transmission and offspring

ES cell targeting allows clones to be screened before mouse production and suits complex modifications, while direct embryo editing (as in Targeted Gene Editing-Pro) can offer a shorter route for simpler edits. The approaches overlap, as gene-editing tools can also be used in ES cells.

The BALB/c challenge. Historically, germline-competent ES cell lines came mainly from 129 or C57BL/6 backgrounds, and BALB/c lines were less available. Complex alleles were therefore often made on another background and backcrossed to BALB/c, typically for at least 10 generations (two years or more). Marker-assisted (speed congenic) breeding can shorten this to around five generations, although donor DNA linked to the targeted locus may remain.

Cyagen's BALB/c solution. Cyagen's TurboKnockout™ uses BALB/c ES cells to generate complex models directly on a BALB/c background, potentially reducing the need for extensive backcrossing from a different strain.

If your research calls for a custom BALB/c or C57BL/6 model, contact our team to discuss the best strategy for your project.

References

[1] Mouse Genome Sequencing Consortium. Initial sequencing and comparative analysis of the mouse genome. Nature. 2002 Dec 5;420(6915):520-62. doi: 10.1038/nature01262. PMID: 12466850.

[2] Belknap JK, Crabbe JC, Young ER. Voluntary consumption of ethanol in 15 inbred mouse strains. Psychopharmacology (Berl). 1993;112(4):503-10. doi: 10.1007/BF02244901. PMID: 7871064.

[3] Medina E, North RJ. Resistance ranking of some common inbred mouse strains to Mycobacterium tuberculosis and relationship to major histocompatibility complex haplotype and Nramp1 genotype. Immunology. 1998 Feb;93(2):270-4. doi: 10.1046/j.1365-2567.1998.00419.x. PMID: 9616378; PMCID: PMC1364188.

[4] Noben-Trauth K, Zheng QY, Johnson KR. Association of cadherin 23 with polygenic inheritance and genetic modification of sensorineural hearing loss. Nat Genet. 2003 Sep;35(1):21-3. doi: 10.1038/ng1226. Epub 2003 Aug 10. PMID: 12910270; PMCID: PMC2864026.

[5] Mekada K, Abe K, Murakami A, Nakamura S, Nakata H, Moriwaki K, Obata Y, Yoshiki A. Genetic differences among C57BL/6 substrains. Exp Anim. 2009 Apr;58(2):141-9. doi: 10.1538/expanim.58.141. PMID: 19448337.

[6] Toye AA, Lippiat JD, Proks P, Shimomura K, Bentley L, Hugill A, Mijat V, Goldsworthy M, Moir L, Haynes A, Quarterman J, Freeman HC, Ashcroft FM, Cox RD. A genetic and physiological study of impaired glucose homeostasis control in C57BL/6J mice. Diabetologia. 2005 Apr;48(4):675-86. doi: 10.1007/s00125-005-1680-z. Epub 2005 Feb 24. PMID: 15729571.

[7] Mattapallil MJ, Wawrousek EF, Chan CC, Zhao H, Roychoudhury J, Ferguson TA, Caspi RR. The Rd8 mutation of the Crb1 gene is present in vendor lines of C57BL/6N mice and embryonic stem cells, and confounds ocular induced mutant phenotypes. Invest Ophthalmol Vis Sci. 2012 May 17;53(6):2921-7. doi: 10.1167/iovs.12-9662. PMID: 22447858; PMCID: PMC3376073.

[8] Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975 Aug 7;256(5517):495-7. doi: 10.1038/256495a0. PMID: 1172191.

[9] Sacks D, Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol. 2002 Nov;2(11):845-58. doi: 10.1038/nri933. PMID: 12415308.

[10] Esteban DJ, Buller RML. Ectromelia virus: the causative agent of mousepox. J Gen Virol. 2005 Oct;86(Pt 10):2645-2659. doi: 10.1099/vir.0.81090-0. PMID: 16186218.

[11] Sellers RS, Clifford CB, Treuting PM, Brayton C. Immunological variation between inbred laboratory mouse strains: points to consider in phenotyping genetically immunomodified mice. Vet Pathol. 2012 Jan;49(1):32-43. doi: 10.1177/0300985811429314. Epub 2011 Nov 30. PMID: 22135019.

[12] Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol. 2000 Jun 15;164(12):6166-73. doi: 10.4049/jimmunol.164.12.6166. PMID: 10843666.

[13] Liu T, Nishimura H, Matsuguchi T, Yoshikai Y. Differences in interleukin-12 and -15 production by dendritic cells at the early stage of Listeria monocytogenes infection between BALB/c and C57 BL/6 mice. Cell Immunol. 2000 May 25;202(1):31-40. doi: 10.1006/cimm.2000.1644. PMID: 10873304.

[14] Post AM, Weyers P, Holzer P, Painsipp E, Pauli P, Wultsch T, Reif A, Lesch KP. Gene-environment interaction influences anxiety-like behavior in ethologically based mouse models. Behav Brain Res. 2011 Mar 17;218(1):99-105. doi: 10.1016/j.bbr.2010.11.031. Epub 2010 Nov 24. PMID: 21111005.

[15] Johnson KR, Zheng QY, Erway LC. A major gene affecting age-related hearing loss is common to at least ten inbred strains of mice. Genomics. 2000 Dec 1;70(2):171-80. doi: 10.1006/geno.2000.6377. PMID: 11112345.

Subscribe to Receive Updates & Promotions From Cyagen
Subscribe
* Your privacy matters to us. We never share it with third parties.
Explore More
siRNA Goes Public Again: CITY vs Alnylam and the In Vivo Models Behind the Next Wave
AI Antibody Discovery: From Designed Binders to Validated Drug Candidates
ALK7 Obesity Target: What Roche's $1.16B Rona RNAi Deal Means for Fat-Focused Drug Discovery
More Opsin, or a Different Target? The Delivery Question Behind This Year's Optogenetics Nobel
Share
Top
Ready to Elevate Your Research?
Discover how Cyagen can support your research. Let’s start a conversation.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0336
Email:
inquiry@cyagen.com
Services
HUGO-GT™HUGO-Ab™iPSC Cell LinesAdeno-associated Virus (AAV) Standard Capsid
Drug R&D
NeurologyMetabolicOphthalmologyOncology
About Us
Animal Health & WelfareCompany OverviewOur TeamHealth Reports
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2026 Cyagen. All rights reserved.
Privacy Policy
Site Map
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest
Main Area of Research